The "dip" was primarily triggered by releasing positive Phase 2b data for its drug efruxifermin in patients with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis).
: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat. MadrigalВ Dip
Investment firms, including and Piper Sandler , maintain a bullish outlook despite the price drop: The "dip" was primarily triggered by releasing positive
